Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Full year results due out on Monday 28th November according to Stockopedia.
GLA
Let's hope we get some positive news regarding Croda scale-up (i.e. has it been optimised yet), VIP likely launch date, expectations for completing the axisbiotix multi national distribution partner pillar contract (mindful that progress on the medi and clean biotix pillars seems to have dragged on for years with no reported progress). In terms of axisbiotix revenues, using the £75000 revenue to end June figure divided by the estimated orders over the 8 mth period (1200 based on mid june order number uplift), gives an average order value of £62.5. Over the last 5 months using an uplift of the latest Nov order number and average price, revenues are guestimated to have increased to £102K over the last 5 months (136% uplift over a shorter period) so marketing is kicking in but from a low base and a long way to go to achieve real penetration in the psoriasis population.
Totally agree Aquae, I’m hoping for a mention on all those points. My calculations on revenue since year end are similar to yours, and hopefully the market is expecting similar.
I see this release as a real opportunity for SA to action his promises about better RNS communication he made after the revenue/distribution deal debacle. The less gaps he leaves the less space he leaves for the markets imagination to run wild. He needs to regain his lost position as the solid and reliable CEO we know he is.
We have been in the dark as to a multi-national deal and Croda's rollout to their clients, if either is not forthcoming or NDC this would be a disappointment. Let's hope this is not the case!
There is lots of potential to disappoint the markets with this RNS. It’s the first time ever as an investor in this company I’ve been tempted to sell ahead of the release, which says something I didn’t want to hear about my subconscious sentiment. Logically, this company has a lot going for it. If information about Croda’s rollout or an Axis deal is hidden behind an NDA, I think it would be satisfactory to say something is happening but can’t be revealed because of the NDA, along with a guide to timescales. If nothing is mentioned about something, the market will not give the team credit for the hard work they are doing on that pillar in the background.
The several multi-national deals being tabled that Ashman has alluded to will ensure the company's resilience.
Looking forward to the next update, hopefully this week, guess tomorrow or Thursdayasre favourites.
Well assuming the next update is the End of Year Financials you are probably the only one looking forward to it Bel.
It will be interesting to see what Stuart has to say about what on the face of it look like a number of upcoming missed targets (extracted from End 2021 EOY Results RNS); hope I am wrong and each target is still hit by end Dec
"Key highlights
· Formulation blend of probiotic food supplement, AxisBiotix-Ps™, produced ahead of schedule
· Completion of consumer study of AxisBiotix-Ps™ with strong final results from participants who self-identified as having mild to moderate psoriasis
· Croda-SkinBiotix® programme continued to progress to plan, with focus on scaling up lysate manufacture to commercial volumes
· Potential additional cosmetic claims for SkinBiotix® being investigated. Initial royalty revenues anticipated as planned in calendar year 2022
· Placing and open offer completed in November 2020 raising £4.45m (gross)
· Cash as at 30 June 2021 of £4.6m (2020: £2.2m)
Post year end:
· Successful product launch of AxisBiotix-Ps™ 12 months earlier than intended. Early sales in the UK and US have commenced; expansion into Europe to occur in H1 2022
· Targeting acne as the next AxisBiotix opportunity; plans to develop a bacterial blend and initiate a consumer study during 2022"
Regarding the 2021 results RNS pasted below by Aquae, it wasn’t a bad RNS at the time, but if memory serves me correctly the SP dropped about 20% before recovering.
yes when you see the raft of sells today, it does bring a sense of foreboding. Hope I'm wrong but seen similar leakage signals before.
Tomorrow should be interesting,
Yes but I expect England to win 3-0
Well Phat you were right, yesterday was an interesting day England 3 Wales 0 was a seven bagger for me :)
Fair play Aquae, dont follow it myself but you called it spot on. Enjoy your winnings! ;-)